JP6674903B2 - Ｓ１ｐ調節剤即時放出投与レジメン - Google Patents

Ｓ１ｐ調節剤即時放出投与レジメン Download PDF

Info

Publication number
JP6674903B2
JP6674903B2 JP2016561731A JP2016561731A JP6674903B2 JP 6674903 B2 JP6674903 B2 JP 6674903B2 JP 2016561731 A JP2016561731 A JP 2016561731A JP 2016561731 A JP2016561731 A JP 2016561731A JP 6674903 B2 JP6674903 B2 JP 6674903B2
Authority
JP
Japan
Prior art keywords
siponimod
day
dosage form
patient
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016561731A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017510607A5 (enExample
JP2017510607A (ja
Inventor
ルギャンヌ，エリック
ウォールストローム，エリック
マイケル ルネ ブイロット，フィリップ
マイケル ルネ ブイロット，フィリップ
レイノール，エメリック
ダルク，フランク
Original Assignee
ノバルティス アーゲー
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52988364&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6674903(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ノバルティス アーゲー, ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2017510607A publication Critical patent/JP2017510607A/ja
Publication of JP2017510607A5 publication Critical patent/JP2017510607A5/ja
Application granted granted Critical
Publication of JP6674903B2 publication Critical patent/JP6674903B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2016561731A 2014-04-10 2015-04-08 Ｓ１ｐ調節剤即時放出投与レジメン Active JP6674903B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461977816P 2014-04-10 2014-04-10
US61/977,816 2014-04-10
PCT/IB2015/052550 WO2015155709A1 (en) 2014-04-10 2015-04-08 S1p modulator immediate release dosage regimen

Publications (3)

Publication Number Publication Date
JP2017510607A JP2017510607A (ja) 2017-04-13
JP2017510607A5 JP2017510607A5 (enExample) 2018-05-17
JP6674903B2 true JP6674903B2 (ja) 2020-04-01

Family

ID=52988364

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016561731A Active JP6674903B2 (ja) 2014-04-10 2015-04-08 Ｓ１ｐ調節剤即時放出投与レジメン

Country Status (16)

Country Link
US (4) US20170027907A1 (enExample)
EP (3) EP4074312A1 (enExample)
JP (1) JP6674903B2 (enExample)
KR (2) KR20220156981A (enExample)
CN (2) CN116650467A (enExample)
AU (2) AU2015246036A1 (enExample)
CA (1) CA2943598C (enExample)
CL (1) CL2016002562A1 (enExample)
IL (2) IL305337A (enExample)
MX (1) MX2016013245A (enExample)
PH (1) PH12016501965A1 (enExample)
RU (2) RU2020107732A (enExample)
SG (1) SG11201607894RA (enExample)
TW (1) TW201622721A (enExample)
WO (1) WO2015155709A1 (enExample)
ZA (1) ZA201606519B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2699580T3 (enExample) 2014-01-24 2018-02-24
MX2016013245A (es) * 2014-04-10 2017-01-16 Novartis Ag Regimen de dosificacion de liberacion inmediata de moduladores s1p.
US11629124B2 (en) 2017-03-09 2023-04-18 Novartis Ag Solid forms comprising an oxime ether compound, compositions and methods of use thereof
US11434200B2 (en) 2017-03-09 2022-09-06 Novartis Ag Solid forms comprising an oxime ether compound and a coformer, compositions and methods of use thereof
US20200316021A1 (en) * 2017-09-29 2020-10-08 Novartis Ag Dosing Regimen of Siponimod
CN111132677A (zh) * 2017-09-29 2020-05-08 诺华股份有限公司 西尼莫德的给药方案
HRP20250115T1 (hr) * 2018-03-01 2025-05-23 Astrazeneca Ab Farmaceutski pripravci koji sadrže (2s)-{(1s)-1-cijano-2-[4-(3-metil-2-okso-2,3-dihidro-1,3-benzoksazol-5-il)fenil]etil} -1,4-oksazepan-2-karboksamid
CA3106269A1 (en) 2018-07-17 2020-01-23 Insmed Incorporated Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating lupus nephritis
CN109908095A (zh) * 2019-04-08 2019-06-21 肇庆学院 一种西尼莫德片剂及制备方法
PH12022551043A1 (en) 2019-10-31 2023-05-03 Idorsia Pharmaceuticals Ltd Combination of a cxcr7 antagonist with an s1p1 receptor modulator
WO2021158838A1 (en) * 2020-02-07 2021-08-12 Argentum Pharmaceuticals Llc Dosage regimen of an s1p receptor modulator
AU2024206233A1 (en) 2023-01-06 2025-08-21 Insmed Incorporated Novel, reversible dpp1 inhibitors and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG171785A1 (en) * 2008-12-18 2011-07-28 Novartis Ag Hemifumarate salt of 1- [4- [1- ( 4 -cyclohexyl-3 -trifluoromethyl-benzyloxyimino ) -ethyl] -2 -ethyl-benzyl] -a zetidine-3-carboxylic acid
MX367667B (es) 2008-12-22 2019-08-30 Novartis Ag Régimen de dosificación de un agonista de los receptores de s1p.
DK2379067T3 (en) * 2008-12-22 2015-12-07 Novartis Ag Dosing regimen to fingolimod FOR THE TREATMENT OF MULTIPLE SCLEROSIS
CA2773330C (en) * 2009-09-29 2021-11-02 Novartis Ag Dosage regimen of an s1p receptor modulator
BR112013017302B1 (pt) * 2011-01-07 2021-12-07 Novartis Ag Composição farmacêutica em fase sólida
WO2012095853A1 (en) 2011-01-10 2012-07-19 Novartis Pharma Ag Modified release formulations comprising sip receptor modulators
KR20140084041A (ko) * 2011-10-21 2014-07-04 노파르티스 아게 S1p 수용체 조절제 또는 효능제에 대한 투여 요법
MX2016013245A (es) * 2014-04-10 2017-01-16 Novartis Ag Regimen de dosificacion de liberacion inmediata de moduladores s1p.

Also Published As

Publication number Publication date
EP4074312A1 (en) 2022-10-19
CA2943598C (en) 2023-03-07
US20220016076A1 (en) 2022-01-20
SG11201607894RA (en) 2016-10-28
MX2016013245A (es) 2017-01-16
RU2016143979A (ru) 2018-05-14
US20190054065A1 (en) 2019-02-21
US20250041266A1 (en) 2025-02-06
ZA201606519B (en) 2017-11-29
JP2017510607A (ja) 2017-04-13
CL2016002562A1 (es) 2017-07-28
RU2715734C2 (ru) 2020-03-03
RU2016143979A3 (enExample) 2018-11-12
EP3831378A1 (en) 2021-06-09
AU2020203107B2 (en) 2021-10-21
IL247986A0 (en) 2016-11-30
CA2943598A1 (en) 2015-10-15
AU2015246036A1 (en) 2016-10-13
CN106456552A (zh) 2017-02-22
KR20160141841A (ko) 2016-12-09
CN116650467A (zh) 2023-08-29
PH12016501965A1 (en) 2017-01-09
EP3129020A1 (en) 2017-02-15
KR20220156981A (ko) 2022-11-28
US20170027907A1 (en) 2017-02-02
AU2020203107A1 (en) 2020-05-28
IL305337A (en) 2023-10-01
TW201622721A (zh) 2016-07-01
RU2020107732A (ru) 2020-03-30
WO2015155709A1 (en) 2015-10-15

Similar Documents

Publication Publication Date Title
JP6674903B2 (ja) Ｓ１ｐ調節剤即時放出投与レジメン
JP6244497B1 (ja) 選択的ｓ１ｐ１レセプターアゴニストの投与法
JP6731915B2 (ja) 多発性硬化症治療用のシポニモドとラキニモドを含む組み合わせ
CA2682015A1 (en) Pharmaceutical compositions comprising flibanserin and a further agent in the treatment of sexual disorders
JP2018039817A (ja) 多発性硬化症を治療するためのＰＰＡＲγアゴニスト
CN105163737A (zh) 用拉喹莫德治疗多发性硬化症
KR20200062241A (ko) 시포니모드의 투여 요법
US20200253959A1 (en) Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic diseases
JP7539898B2 (ja) オピオイド鎮痛耐性を治療するためのｍＧｌｕＲ５アンタゴニストの使用
KR20200062240A (ko) 시포니모드의 투여 요법
US11179377B2 (en) Pharmaceutical compositions and uses thereof
JP2019038858A (ja) ペマフィブラートを含有する医薬
HK40053433A (en) Siponimod immediate release dosage regimen for treating autoimmune diseases
HK40081576A (en) Siponimod immediate release dosage regimen for treating autoimmune diseases
CN1738626A (zh) 含有桂利嗪和茶苯海明的抗眩晕的组合制剂
TW202527911A (zh) 用於治療猝睡症的化合物
JP2024518787A (ja) 全身型重症筋無力症の処置のための補体因子ｄ阻害剤の使用
TW202237084A (zh) 修飾釋放調配物及其用途
CA2973540A1 (en) Treatment of autoimmune disease in a patient receiving additionally a beta-blocker

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180326

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180326

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181211

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190308

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190507

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190611

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190924

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191223

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200303

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200309

R150 Certificate of patent or registration of utility model

Ref document number: 6674903

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250